[HTML][HTML] The effect of sorafenib on liver regeneration and angiogenesis after partial hepatectomy in rats
K Kiroplastis, I Fouzas, E Katsiki, K Patsiaoura… - Hippokratia, 2015 - ncbi.nlm.nih.gov
Background Liver regeneration is vital for the survival of patients submitted to extensive liver
resection as a treatment of hepatocellular carcinoma (HCC). Sorafenib is a multikinase …
resection as a treatment of hepatocellular carcinoma (HCC). Sorafenib is a multikinase …
Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats
KJ Andersen, AR Knudsen, AS Kannerup… - Journal of Surgical …, 2014 - Elsevier
Background Sorafenib, a multikinase inhibitor, has been shown to halt the growth of
hepatocellular carcinoma. The aim of the present study was to investigate the effect of …
hepatocellular carcinoma. The aim of the present study was to investigate the effect of …
Sorafenib prolongs liver regeneration after hepatic resection in rats
A Mollbrink, M Augsten, R Hultcrantz… - journal of surgical …, 2013 - Elsevier
Background The multikinase inhibitor sorafenib inhibits angiogenesis and tumor cell
proliferation. Sorafenib targets signaling pathways involved in liver regeneration. Previous …
proliferation. Sorafenib targets signaling pathways involved in liver regeneration. Previous …
The effects of sorafenib on liver regeneration in a model of partial hepatectomy
PC Kurniali, K O'Gara, X Wang, LJ Wang… - journal of surgical …, 2012 - Elsevier
BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …
[PDF][PDF] Effect of sorafenib on murine liver regeneration
C Hora, P Romanque, JFF Dufour - Hepatology, 2011 - Wiley Online Library
Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …
prolongs survival of patients with advanced disease and is approved for the systemic …
Sorafenib inhibits liver regeneration in rats
KJ Andersen, AR Knudsen, AS Kannerup… - HPB, 2013 - Wiley Online Library
Background Sorafenib is a multikinase inhibitor with antiangiogenic and antiproliferative
properties, approved for the treatment of hepatocellular carcinoma. The effect of S orafenib …
properties, approved for the treatment of hepatocellular carcinoma. The effect of S orafenib …
[PDF][PDF] Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model
Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …
RAF‐targeted therapy for hepatocellular carcinoma in the regenerating liver
Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular …
Z Wang, J Hu, SJ Qiu, XW Huang, Z Dai… - Expert opinion on …, 2011 - Taylor & Francis
Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …
recurrence and metastasis after curative resection of liver cancer. Research methods …
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis
M Hennenberg, J Trebicka, Z Kohistani, C Stark… - Laboratory …, 2011 - nature.com
Portal hypertension in cirrhosis depends on increased intrahepatic vascular resistance,
which is explained by fibrosis and intrahepatic hyperresponsiveness to vasoconstrictors …
which is explained by fibrosis and intrahepatic hyperresponsiveness to vasoconstrictors …